Cited 0 times in
Response to three years of growth hormone therapy in girls with Turner syndrome
|dc.description.abstract||Purpose: Short stature is the most common finding in patients with Turner syndrome. Improving the final adult height in these patients is a challenge both for the patients and physicians. We investigated the clinical response of patients to growth hormone treatment for height improvement over the period of three years.
Methods: Review of medical records from 27 patients with Turner syndrome treated with recombinant human growth hormone for more than 3 years was done. Differences in the changes of height standard deviation scores according to karyotype were measured and factors influencing the height changes were analyzed.
Results: The response to recombinant human growth hormone was an increase in the height of the subjects to a mean value of 1.1 standard deviation for subjects with Turner syndrome at the end of the 3-year treatment. The height increment in the first year was highest. The height standard deviation score in the third year was negatively correlated with the age at the beginning of the recombinant human growth hormone treatment. Different karyotypes in subjects did not seem to affect the height changes.
Conclusion: Early growth hormone administration in subjects with Turner syndrome is helpful to improve height response to the treatment.
|dc.title||Response to three years of growth hormone therapy in girls with Turner syndrome||-|
|dc.citation.title||Annals of pediatric endocrinology & metabolism||-|
|dc.identifier.bibliographicCitation||Annals of pediatric endocrinology & metabolism, 18(1):13-18, 2013||-|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.